Wael Fayad and Stephen Hallenbeck Appointed Partners at Hildred Capital Management

NEW YORK--(BUSINESS WIRE)--Hildred Capital Management (“Hildred”), a healthcare-focused private equity firm that seeks opportunities to create value in middle-market companies, today announced that Wael Fayad and Stephen Hallenbeck have both been appointed Partners at the firm.

On behalf of Hildred, Co-Founders and Managing Partners Andrew Goldman and David Solomon stated:

"We are pleased to announce the promotions of Wael and Stephen, which reflect the vital impact and contributions that each of them has had on the growth of our firm.

Wael is an integral part of our team and has been intimately involved in strategically managing several of our portfolio companies, including Carlin Consumer Health, Hyland’s Naturals, and Crown Laboratories. He has consistently demonstrated a unique ability to work closely with business leaders to drive results and has a proven track record of leveraging his extensive experience in the healthcare industry and his broad network of relationships to support our portfolio companies’ growth trajectories.

Stephen has been a critical part of our investment team's success for more than eight years, and has been responsible for sourcing, evaluating, executing, and managing numerous opportunities, notably including DermCare, SportsMed, Crown Laboratories, AleraCare and Orange Twist. The depth and breadth of his investment acumen, coupled with his deep expertise across healthcare, has been a valuable combination in helping our firm grow and deliver attractive risk adjusted returns to our investors.”

Before Hildred, Mr. Fayad spent more than 25 years in pharma and biotech. He started his career in sales, marketing, and new products at Novartis and Schering-Plough. He then worked at Forest Laboratories Inc. for 14 years and served as Corporate Vice President of Business Development. Subsequent to Forest, he advised and worked with several biotech and start-up life sciences companies including co-founding Accoy Pharmaceuticals and serving as Chairman and CEO of Enumeral Biomedical.

Prior to joining Hildred, Mr. Hallenbeck worked at Deutsche Bank within the Financial Sponsors Group as a member of the firm’s Healthcare Investment Banking team, focusing on M&A, debt, and equity transactions for both private and public companies within the sector.

About Hildred Capital Management
Hildred Capital Management is a healthcare-focused private equity firm that seeks opportunities to create value in middle-market companies. The Firm specializes in partnering with management teams to help them scale their platforms, generate earnings growth, promote strategic and operational improvements, generate business development, and drive multiple expansion. For more information, please visit www.hildredcapital.com and follow the Firm on LinkedIn.